|
1
|
Pisani P, Bray F and Parkin DM: Estimates
of the world-wide prevalence of cancer for 25 sites in the adult
population. Int J Cancer. 97:72–81. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akhmedkhanov A, Zeleniuch-Jacquotte A and
Toniolo P: Role of exogenous and endogenous hormones in endometrial
cancer: Review of the evidence and research perspectives. Ann NY
Acad Sci. 943:296–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matias-Guiu X, Catasus L, Bussaglia E,
Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P and
Prat J: Molecular pathology of endometrial hyperplasia and
carcinoma. Hum Pathol. 32:569–577. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shiozawa T and Konishi I: Early
endometrial carcinoma: Clinicopathology, hormonal aspects,
molecular genetics, diagnosis, and treatment. Int J Clin Oncol.
11:13–21. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tashiro H, Blazes MS, Wu R, Cho KR, Bose
S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
|
6
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA and PTEN genes
in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang
Y, Song L, Yuan X, Wei L, Roden RB, et al: Identification of
molecular pathway aberrations in uterine serous carcinoma by
genome-wide analyses. J Natl Cancer Inst. 104:1503–1513. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Welcker M and Clurman BE: FBW7 ubiquitin
ligase: A tumour suppressor at the crossroads of cell division,
growth and differentiation. Nat Rev Cancer. 8:83–93. 2008.
View Article : Google Scholar
|
|
9
|
Spruck CH, Strohmaier H, Sangfelt O,
Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M
and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer
Res. 62:4535–4539. 2002.PubMed/NCBI
|
|
10
|
Knuutila S, Aalto Y, Autio K, Björkqvist
AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S,
Larramendy ML, et al: DNA copy number losses in human neoplasms. Am
J Pathol. 155:683–694. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Strohmaier H, Spruck CH, Kaiser P, Won KA,
Sangfelt O and Reed SI: Human F-box protein hCdc4 targets cyclin E
for proteolysis and is mutated in a breast cancer cell line.
Nature. 413:316–322. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Izumi N, Helker C, Ehling M, Behrens A,
Herzog W and Adams RH: Fbxw7 controls angiogenesis by regulating
endothelial Notch activity. PLoS One. 7:e411162012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for
ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M:
p53-Altered FBXW7 expression determines poor prognosis in gastric
cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Debies MT and Welch DR: Genetic basis of
human breast cancer metastasis. J Mammary Gland Biol Neoplasia.
6:441–451. 2001. View Article : Google Scholar
|
|
17
|
Albertson DG, Collins C, McCormick F and
Gray JW: Chromosome aberrations in solid tumors. Nat Genet.
34:369–376. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang TL, Diaz LA Jr, Romans K, Bardelli A,
Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, et
al: Digital karyotyping identifies thymidylate synthase
amplification as a mechanism of resistance to 5-fluorouracil in
metastatic colorectal cancer patients. Proc Natl Acad Sci USA.
101:3089–3094. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao TL, Seidman JD, Kurman RJ and Shih
IeM: Cyclin E and p16 immunoreactivity in epithelioid trophoblastic
tumor--an aid in differential diagnosis. Am J Surg Pathol.
30:1105–1110. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rahman M, Nakayama K, Rahman MT, Katagiri
H, Katagiri A, Ishibashi T, Ishikawa M, Iida K and Miyazaki K:
Clinicopathologic analysis of loss of AT-rich interactive domain 1A
expression in endometrial cancer. Hum Pathol. 44:103–109. 2013.
View Article : Google Scholar
|
|
21
|
Rahman MT, Nakayama K, Ishikawa M, Rahman
M, Katagiri H, Katagiri A, Ishibashi T, Iida K and Miyazaki K:
Fatty acid synthase is a potential therapeutic target in estrogen
receptor-/ progesterone receptor-positive endometrioid endometrial
cancer. Oncology. 84:166–173. 2013. View Article : Google Scholar
|
|
22
|
Nakayama K, Miyazaki K, Kanzaki A,
Fukumoto M and Takebayashi Y: Expression and cisplatin sensitivity
of copper-transporting P-type adenosine triphosphatase (ATP7B) in
human solid carcinoma cell lines. Oncol Rep. 8:1285–1287.
2001.PubMed/NCBI
|
|
23
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al;
Cancer Genome Atlas Research Network. Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato N, Watanabe J, Jobo T, Nishimura Y,
Fujisawa T, Kamata Y and Kuramoto H: Immunohistochemical expression
of cyclin E in endometrial adenocarcinoma (endometrioid type) and
its clinicopathological significance. J Cancer Res Clin Oncol.
129:222–226. 2003.PubMed/NCBI
|
|
25
|
Scott M and Hall PA: Prognostic and
predictive factors. Methods Mol Med. 97:1–11. 2004.PubMed/NCBI
|
|
26
|
Hwang HC and Clurman BE: Cyclin E in
normal and neoplastic cell cycles. Oncogene. 24:2776–2786. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geng Y, Lee YM, Welcker M, Swanger J,
Zagozdzon A, Winer JD, Roberts JM, Kaldis P, Clurman BE and
Sicinski P: Kinase-independent function of cyclin E. Mol Cell.
25:127–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cassia R, Moreno-Bueno G,
Rodríguez-Perales S, Hardisson D, Cigudosa JC and Palacios J:
Cyclin E gene (CCNE) amplification and hCDC4 mutations in
endometrial carcinoma. J Pathol. 201:589–595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santala S, Talvensaari-Mattila A, Soini Y
and Santala M: Cyclin E expression correlates with cancer-specific
survival in endometrial endometrioid adenocarcinoma. Anticancer
Res. 35:3393–3397. 2015.PubMed/NCBI
|
|
30
|
Nakayama N, Nakayama K, Shamima Y,
Ishikawa M, Katagiri A, Iida K and Miyazaki K: Gene amplification
CCNE1 is related to poor survival and potential therapeutic target
in ovarian cancer. Cancer. 116:2621–2634. 2010.PubMed/NCBI
|
|
31
|
Pelengaris S and Khan M: The many faces of
c-MYC. Arch Biochem Biophys. 416:129–136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kubben FJ, Sier CF, van Duijn W, Griffioen
G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and
Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic
factor in gastric cancer. Br J Cancer. 94:1035–1040. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Calcagno DQ, Freitas VM, Leal MF, de Souza
CR, Demachki S, Montenegro R, Assumpção PP, Khayat AS, Smith MA,
dos Santos AK, et al: MYC, FBXW7 and TP53 copy number variation and
expression in gastric cancer. BMC Gastroenterol. 13:1412013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao JH, Kim IJ, Wu D, Climent J, Kang HC,
DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and
cooperates with PTEN in tumor suppression. Science. 321:1499–1502.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tu K, Zheng X, Zan X, Han S, Yao Y and Liu
Q: Evaluation of Fbxw7 expression and its correlation with the
expression of c-Myc, cyclin E and p53 in human hepatocellular
carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ibusuki M, Yamamoto Y, Shinriki S, Ando Y
and Iwase H: Reduced expression of ubiquitin ligase FBXW7 mRNA is
associated with poor prognosis in breast cancer patients. Cancer
Sci. 102:439–445. 2011. View Article : Google Scholar
|
|
37
|
Mitsuhashi Y, Horiuchi A, Miyamoto T,
Kashima H, Suzuki A and Shiozawa T: Prognostic significance of
Notch signalling molecules and their involvement in the
invasiveness of endometrial carcinoma cells. Histopathology.
60:826–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Peiró G, Peiró FM, Ortiz-Martínez F,
Planelles M, Sánchez-Tejada L, Alenda C, Ceballos S, Sánchez-Payá J
and Laforga JB: Association of mammalian target of rapamycin with
aggressive type II endometrial carcinomas and poor outcome: A
potential target treatment. Hum Pathol. 44:218–225. 2013.
View Article : Google Scholar
|
|
39
|
Okuda T, Sekizawa A, Purwosunu Y,
Nagatsuka M, Morioka M, Hayashi M and Okai T: Genetics of
endometrial cancers. Obstet Gynecol Int. 2010:9840132010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Llobet D, Pallares J, Yeramian A,
Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X:
Molecular pathology of endometrial carcinoma: Practical aspects
from the diagnostic and therapeutic viewpoints. J Clin Pathol.
62:777–785. 2009. View Article : Google Scholar
|
|
41
|
Ioffe OB, Papadimitriou JC and Drachenberg
CB: Correlation of proliferation indices, apoptosis, and related
oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative,
hyperplastic, and malignant endometrium. Hum Pathol. 29:1150–1159.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sherman ME, Bur ME and Kurman RJ: p53 in
endometrial cancer and its putative precursors: Evidence for
diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weinstein IB, Joe A and Felsher D:
Oncogene addiction. Cancer Res. 68:3077–3080; discussion 3080.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smyth JF, Aamdal S, Awada A, Dittrich C,
Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron
B, et al: Phase II study of E7070 in patients with metastatic
melanoma. Ann Oncol. 16:158–161. 2005. View Article : Google Scholar
|
|
45
|
Talbot DC, von Pawel J, Cattell E, Yule
SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P,
Bosquee L, et al: A randomized phase II pharmacokinetic and
pharmacodynamic study of indisulam as second-line therapy in
patients with advanced non-small cell lung cancer. Clin Cancer Res.
13:1816–1822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nakayama K, Nakayama N, Ishikawa M and
Miyazaki K: Endometrial serous carcinoma: Its molecular
characteristics and histology-specific treatment strategies.
Cancers (Basel). 4:799–807. 2012. View Article : Google Scholar
|
|
47
|
Birkeland E, Wik E, Mjøs S, Hoivik EA,
Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F,
et al: KRAS gene amplification and overexpression but not mutation
associates with aggressive and metastatic endometrial cancer. Br J
Cancer. 107:1997–2004. 2012. View Article : Google Scholar : PubMed/NCBI
|
